AXA’s O’Driscoll: €500m life science deal ‘not a reaction to covid-19′

The head of European transactions at the real assets business of French insurer AXA says the deal to acquire Kadans Science Partner is the outcome of interest in the sector that started more than a year ago.

PRIVATE REAL ESTATE

Register to unlock this content

• Daily global private real estate news and market intelligence
• Expertly curated insights to keep you ahead of the market
• Faster, data-driven decision-making powered by our AI interface, Ask PEI
• Access to proprietary research and reports
• Selected investor strategy and competitor performance data

Register nowFind out more

DealsInvestorsEuropeOpportunisticInsurance Company